What is the global market size of AI in Drug Discovery Market?

AI in Drug Discovery Market size was valued at USD 850 million in 2021 and is poised to grow from USD 1,101.6 million in 2022 to USD 4,982.8 million by 2030, growing at a CAGR of 29.6% during the forecast period (2023-2030).

Ai In Drug Discovery Companies

AI in Drug Discovery Market Competitive Landscape

AI in Drug Discovery Market Top Player’s Company Profiles

IBM Corporation (US)

Google LLC (US)

Microsoft Corporation (US)

NVIDIA Corporation (US)

Insilico Medicine (US)

BenevolentAI Ltd (UK)

Exscientia Ltd (UK)

Atomwise Inc (US)

Berg LLC (US)

XtalPi Inc (China)

Numerate Inc (US)

Cyclica Inc (Canada)

Envisagenics Inc (US)

BioXcel Therapeutics Inc (US)

Recursion Pharmaceuticals Inc (US)

Atomwise Inc (US)

Healx Ltd (UK)

Cloud Pharmaceuticals Inc (US)

TwoXAR Incorporated (US)

Cerebras Systems Inc (US)

AI in Drug Discovery Market

FAQs

AI in Drug Discovery Market size was valued at USD 1,101.6 million in 2022 and is poised to grow from USD 1,427.67 million in 2023 to USD 11,362.37 million by 2031, growing at a CAGR of 29.6% during the forecast period (2024-2031).

The competitive landscape for the global artificial intelligence (AI) in drug discovery industry gives information by competitor. Included information includes a company overview, financials, revenue generated, market potential, R&D investment, new market initiatives, production sites, and facilities, as well as company strengths and weaknesses. It also includes information on product launches, product approval pipelines, product patents, product width and breath, application dominance, and the technology lifeline curve. The company's focus on the global Artificial Intelligence (AI) in drug development market is the only informational item discussed above. 'IBM Corporation (US)', 'Google LLC (US)', 'Microsoft Corporation (US)', 'NVIDIA Corporation (US)', 'Insilico Medicine (US)', 'BenevolentAI Ltd (UK)', 'Exscientia Ltd (UK)', 'Atomwise Inc (US)', 'Berg LLC (US)', 'XtalPi Inc (China)', 'Numerate Inc (US)', 'Cyclica Inc (Canada)', 'Envisagenics Inc (US)', 'BioXcel Therapeutics Inc (US)', 'Recursion Pharmaceuticals Inc (US)', 'Atomwise Inc (US)', 'Healx Ltd (UK)', 'Cloud Pharmaceuticals Inc (US)', 'TwoXAR Incorporated (US)', 'Cerebras Systems Inc (US)'

Around the world, the prevalence of chronic diseases is rising quickly. The Centres for Disease Control and Prevention (CDC) estimate that six out of ten persons in the United States have a chronic illness. The CDC also emphasises that chronic illnesses like diabetes and heart disease are the main killers in the United States. These figures highlight the rising incidence of chronic diseases and the necessity of reducing the death rate brought on by these illnesses. Deriving insights into the identification of medications to treat and lessen the severity of various chronic diseases may show to be a practical alternative using AI platforms utilised for drug research.

The global AI in drug discovery market is characterized by several key market trends that are shaping the industry's landscape. Firstly, there is an increasing adoption of AI technologies as pharmaceutical companies recognize their potential in analyzing complex biological and chemical data. By leveraging AI capabilities, drug discovery processes are becoming more efficient and successful. Collaborations and partnerships are on the rise in AI in drug discovery market. Pharmaceutical companies, technology firms, and academic institutions are joining forces to combine expertise and resources. These collaborations accelerate innovation and knowledge sharing, leading to advancements in AI-driven drug discovery. Overall, these key market trends highlight the transformative impact of AI in drug discovery. By enhancing efficiency, precision, and personalized medicine approaches, AI technologies are shaping the future of pharmaceutical research and development.

North America dominated the global AI in Drug Discovery market. The region benefits from advanced healthcare infrastructure, strong research and development capabilities, and a high adoption rate of AI technologies in the pharmaceutical industry. The presence of key market players, technological advancements, and substantial investments contribute to the region's dominance. Additionally, favorable government initiatives and collaborations between academia, industry, and research institutions further drive the growth of AI in drug discovery in North America.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

AI in Drug Discovery Market Size, Share, Growth Analysis, By Type(Small molecules and Large molecules), By End-User(Pharmaceutical and Biotechnology Companies and Academics and Research institutes), By Region - Industry Forecast 2024-2031

AI in Drug Discovery Market Competitive Landscape

AI in Drug Discovery Market Report Snapshots

Want to customize this report?

FAQs

Request Free Customization

Feedback From Our Clients

$5,300

AI in Drug Discovery Market Size, Share, Growth Analysis, By Type(Small molecules and Large molecules), By End-User(Pharmaceutical and Biotechnology Companies and Academics and Research institutes), By Region - Industry Forecast 2024-2031

AI in Drug Discovery Market Competitive Landscape

AI in Drug Discovery Market Report Snapshots

Want to customize this report?

FAQs

What is the global market size of AI in Drug Discovery Market?

Who are the key vendors in the AI in Drug Discovery Market?

What is the key driver of AI in Drug Discovery Market?

What is the key market trend for AI in Drug Discovery Market?

Which region accounted for the largest share in AI in Drug Discovery Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300